Ocular Therapeutix Inc

-0.04 (-1.29%)
Debt Financing / Related, Earnings Announcements

Ocular Posts Quarterly Net Loss Per Share, Diluted $0.22

Published: 05/09/2022 21:18 GMT
Ocular Therapeutix Inc (OCUL) - Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update.
Ocular Therapeutix - Guiding Dextenza Annual Net Product Revenue for 2022 Between $55 to $60 Million, Representing Annual Growth of About 26% to 38%.
Ocular Therapeutix - Believes Existing Cash, Cash Equivalents, Sufficient to Fund Planned Operating Expenses, Debt Service Obligations, Capex Requirements Through 2023.
Ocular Therapeutix Inc Qtrly Total Revenue, Net $13.2 Million Versus $7.3 Million.
Ocular Therapeutix Inc Qtrly Net Loss per Share, Diluted $0.22.
Revenue is expected to be $14.43 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $15.81 Million
Next Quarter EPS Guidance is expected to be -$0.22

More details on our Analysts Page.